Cell 2025
Cell & Gene Therapy Insights 2025; 11(9), 1125–1127
DOI: 10.18609/cgti.2025.128
As the cell and gene therapy sector accelerates toward industrial maturity, challenges in manufacturing, regulation, and translational development remain at the forefront. Cell 2025, hosted by Oxford Global, will convene leading experts from across academia, industry, and regulation to discuss how the next generation of tools, technologies, and strategies can transform these therapies from concept to clinic. Among the highlights of the program are keynote presentations from Professor Dame Molly Stevens (University of Oxford), whose pioneering work in bionanoscience is redefining regenerative medicine; Dr Bobby Gaspar (Co-Founder & CEO, Orchard Therapeutics), a leading figure in the translation of gene therapies to the clinic; and Professor Christof von Kalle (Charité and BIH), a global authority in clinical and translational sciences. Cell 2025 is being held on November 11–12, 2025 (with a pre-event focus day on November 10) in London, UK.
Smarter bioprocesses
The shift toward data-driven, automated production is redefining what’s possible in cell therapy manufacturing. Presentations in this stream will explore how intelligent bioprocessing and RNA-based technologies are driving speed, reliability, and scalability.
François Gianelli, Chief Regulatory and Quality Officer, TreeFrog Therapeutics, will examine ‘New Manufacturing Modalities for Cell Therapies and Regulatory Challenges’. Gianelli will unpack how emerging bioprocessing innovations are reshaping production whilst examining the evolving regulatory landscape.
Ruth Faram, Co-Founder and Chief Scientific Officer, SymphoRNA, will present on ‘Using RNA to Program In Vivo and Ex Vivo Therapies', showcasing how RNA can be leveraged to precisely reprogram cells both within and outside the body. Her session will highlight how RNA-based modalities are accelerating discovery and enabling more efficient therapeutic development.
These talks underscore the growing intersection between molecular innovation and process optimization–key to achieving true scalability in advanced therapy manufacturing.
Move beyond manual manufacturing
Cell and gene therapy production is still too slow, hands-on, and expensive. Automation and digitalization are no longer optional in advanced therapy production–they are the foundation of efficient, reproducible biomanufacturing.
Ben Weil, Chief Operating Officer and Chief Manufacturing Officer, INmune Bio, will discuss ‘Autologous and Allogeneic Products’, offering strategic insights into the contrasting production demands of patient-specific versus universal therapies. Weil will highlight process control, supply chain optimization, and cost-effectiveness as pivotal factors in making manufacturing commercially viable.
Through these discussions, Cell 2025 aims to spotlight practical routes toward industrialized, automated manufacturing systems that can meet growing clinical demand without compromising on product quality.
Clear the path to approval
As innovation outpaces regulation, achieving alignment between developers and regulators has become a decisive factor in the success of next-generation therapies.
Jon Beaman, Deputy Director, Innovative Medicines, MHRA, will discuss an ‘Overview of the UK Cell and Gene Therapy Market’. His presentation will highlight the UK’s expanding clinical trial landscape, strong investment environment, and national strategy for maintaining global leadership in advanced therapies.
Nitin Patel, Vice President of Late-Stage Clinical Development, Legend Biotech, will contribute with ‘Late-Stage Clinical Development for the Cilta-Cel Program’.Patel will share insights from the ongoing development of the Cilta-Cel CAR-T therapy, exploring lessons in trial design, data outcomes, and regulatory progress toward commercial readiness.
Cell 2025 will provide a comprehensive view of how regulators and industry can collaborate to accelerate safe, effective patient access.
Rethink pre-clinical models
Understanding efficacy and safety before entering the clinic remains a defining challenge for cell and gene therapy development.
Liz Ramsburg, Head of Research, Roche Innovation Center Philadelphia, will discuss ‘Advances in Gene Therapy Development’, outlining how new pre-clinical tools and translational strategies are informing smarter development pipelines. Her insights will connect early discovery science with the downstream manufacturing and clinical considerations shaping the next generation of gene therapies.
Terri Gaskell, Chief Technology Officer, Rinri Therapeutics, will present on ‘Trial Design and Patient Engagement’, addressing how improved trial structures and patient-centric approaches can strengthen both recruitment and data robustness, bridging the gap between pre-clinical promise and clinical delivery.
These talks highlight how integrating predictive models with meaningful patient engagement is essential for reducing attrition and accelerating therapeutic translation.
Across two focused days, Cell 2025 will offer in-depth discussions, case studies, and panel sessions exploring how automation, bioprocessing technologies, and adaptive regulation are converging to advance cell and gene therapy manufacturing.
The meeting promises to be a key opportunity for industry and academic leaders alike to share best practices, shape collaborative frameworks, and define the future of advanced biomanufacturing. You can use the link here to register for Cell 2025.
Additionally, to find out what other cell and gene therapy events are upcoming, you can find our online Events Calendar here.